Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/17/25 Mineralys (MLYS) Lorundrostat for Chronic Kidney Disease (CKD) Subscribers Only Subscribers Only Subscribers Only
6/17/25 Mineralys (MLYS) Lorundrostat for Hypertension (Systemic) Subscribers Only Subscribers Only Subscribers Only
6/16/25 D&D Pharmatech DD-01 for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
6/14/25 Tonix Pharmaceuticals Holding (TNXP) TNX-102 SL for Fibromyalgia Subscribers Only Subscribers Only Subscribers Only
6/13/25 Swedish Orphan Biovitrum (SOBI) Gamifant for Histiocytosis Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/02/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update